Buruli ulcer is a neglected tropical disease caused by *Mycobacterium ulcerans*, an environmental mycobacterium. This skin infection, which mostly affects children, has emerged or re-emerged in the last 2 decades, particularly around the Gulf of Guinea in West Africa \[[@OFW013C1]\]. The route of transmission has yet to be clearly determined, but inoculation of the derma with the bacterium appears to be necessary \[[@OFW013C2]\]. After an estimated incubation period of a few weeks to several months, *M ulcerans* causes necrotizing hypodermitis, in the form of a nodule, an edema, or a plaque \[[@OFW013C3]\]. After destruction of the subcutaneous tissue (caused by a cytotoxic, immunosuppressive and analgesic toxin called mycolactone \[[@OFW013C4]--[@OFW013C6]\]), the skin may break down, leading to the development of largely painless necrotic ulcers with characteristic undermined edges \[[@OFW013C7]\].

No specific vaccine against Buruli ulcer is currently available. Bacillus Calmette-Guérin (BCG) vaccination was initially thought to have incomplete but significant short-term protective effects \[[@OFW013C8], [@OFW013C9]\] or to confer partial protection against *M ulcerans* osteomyelitis \[[@OFW013C10]\]. However, other studies provided no evidence of a protective effect \[[@OFW013C11], [@OFW013C12]\] or even reported a higher risk of Buruli ulcer in adults and children over the age of 5 years that had been vaccinated with BCG \[[@OFW013C13]\].

The severity of Buruli ulcer lesions depends on their form, extent, and localization \[[@OFW013C14]\]. Indeed, early lesions (nonulcerative) may differ in clinical appearance (taking the form of a nodule, plaque, or edema), and these different forms progress differently. For example, a nodule may spontaneously progress to a small circumscribed ulcer, whereas an edema of the entire limb generally progresses to extensive ulceration with severe functional impairment \[[@OFW013C14], [@OFW013C15]\]. Other factors may also determine the severity of Buruli ulcer. These factors include human immunodeficiency virus coinfection \[[@OFW013C16]--[@OFW013C18]\] and time from onset to first consultation (which depends partly on local healthcare management) \[[@OFW013C19], [@OFW013C20]\].

Small Buruli ulcer lesion can be treated with a combination of rifampin and an aminoglycoside for 8 weeks, but larger lesions require additional extensive surgery in dedicated hospitals \[[@OFW013C21]--[@OFW013C23]\]. Even in cases of effective medical treatment, more than 20% of patients present permanent functional sequelae 1 year later \[[@OFW013C14]\].

If left untreated, Buruli ulcers progress to chronic ulcerations with a risk of dissemination and bone destruction \[[@OFW013C14], [@OFW013C19], [@OFW013C24]\]. Although many publications mention the occurrence of spontaneous healing in some patients, the process remains poorly described or studied \[[@OFW013C7], [@OFW013C25]--[@OFW013C32]\]. Questions thus remain unresolved: Are healing cases rare in the Buruli ulcer context? What are the principal clinical features of this healing process?

In this context, we performed a retrospective study in a highly specialized Buruli ulcer diagnosis and treatment center in Benin. Moreover, we provide a comprehensive description of the various clinical presentations of the spontaneous partial healing of Buruli ulcer.

METHODS AND RESULTS {#s2}
===================

Study Design, Data Collection, and Definitions {#s2a}
----------------------------------------------

A retrospective study was conducted at the Centre de Diagnostic et de Traitement de la Lèpre et de l′Ulcère de Buruli (CDTLUB) in Pobè, Benin, which has one of the largest databases for cases of Buruli ulcer confirmed by polymerase chain reaction (PCR) \[[@OFW013C14]\].

We first conducted a preliminary analysis of 545 Buruli ulcer patients treated at the CDTLUB in Pobè from 2010 to 2013. For the selection of medical records, we used several key words defined on the basis of publications in this field: spontaneous healing, spontaneous clearance, scar, old ulcer, scarring lesion. During this review step, medical records containing at least 1 of the chosen key words were selected. If the clinical records were incomplete (eg, lack of photographic monitoring, patients lost to follow-up), the patient was excluded.

The preselected clinical records were then fully examined and patient information was collected (including age, sex, date of onset, date of diagnosis, clinical features, past medical history, medical and laboratory analysis, lesion examination, imaging data, and clinical monitoring). None of the patients received pharmacological treatment for mycobacterial infection before consulting at the Centre de Dépistage et de Traitement de l\'Ulcère de Buruli (CDTUB) Pobè.

Cohort Presentation {#s2b}
-------------------

We selected 26 patients (sex ratio M/F =1.4), on the basis of our criteria, from the database of the CDTLUB. Median patient age at diagnosis was 13.5 years (5--70 years), with female patients tending to be older than male patients (Figure [1](#OFW013F1){ref-type="fig"}). The age distribution of male and female patients was similar to that for the entire population of 545 Buruli ulcer patients from 2010 to 2013 (Figure [1](#OFW013F1){ref-type="fig"}). Figure 1.Age distribution, by sex, of Buruli ulcer patients in the spontaneous healing cohort and in the general cohort of patients seen between 2010 and 2013. The age distribution is similar for the 2 cohorts, with female patients older than male patients in both cohorts. Mann--Whitney *U* test; \**P* \< .05, \*\*\**P* \< .0001.

Almost all the patients (25 of 26) had category 3 lesions (World Health Organization nomenclature) presenting as single lesions of more than 15 cm in diameter or osteomyelitis, or multiple lesions, and/or lesions at critical sites. In 85% of patients (22 of 26), lesions were present on the lower limbs (59% for the total cohort, *P* \< .05, Fisher test). Three patients presented multiple active Buruli ulcer lesions (2 patients with 2 lesions, 1 patient with 3 lesions).

We found that 77% (20 of 26) of patients had waited at least 1 year after the first signs of an active lesion before consulting at the CDTUB Pobè (13% for the total cohort, *P* \< .001, Fisher test). Complete physical examination of body showed that 13 of the 26 patients had a healed scar with a stellate appearance consistent with an old Buruli ulcer lesion at some distance from the active lesion. An exhaustive study of the clinical records of each patient, including the clinical features of the lesion and the medical history of the patient, led us to define 3 groups on the basis of the healing process observed, as described below.

Group 1: Spontaneous Healing Process in Progress {#s2c}
------------------------------------------------

Patients of this group (n = 12) typically had an ulcer that had been present on a limb for more than 1 year and was healing (Table [1](#OFW013TB1){ref-type="table"}). Seven of the 12 patients in this group were male (median age = 9 years) and 5 were female (median age = 25 years). The edges of the lesion were defined by skin repair and re-epithelialization processes (Figure [2](#OFW013F2){ref-type="fig"}). The lesions typically displayed no edema, plaque, necrosis, or acute inflammation (Figure [2](#OFW013F2){ref-type="fig"}). Despite the lack of specific clinical signs of Buruli ulcer, microbiological analysis based on PCR (73%), acid-fast bacilli (45%), and culture (9%) demonstrated the presence of *M ulcerans* infection (9%) (Table [1](#OFW013TB1){ref-type="table"}). Swabbing was difficult because the edges of the lesions had healed. Biological confirmation was obtained principally by biopsy during surgical repair (eg, debridement, skin graft). Most patients (75%) presented physical impairment on arrival at the center and, even with combined drug treatment and surgery, this impairment was irreversible in 42% of patients (Table [1](#OFW013TB1){ref-type="table"}). The need for surgery and rehabilitation resulted in hospitalization for 2 to 7 months. In 1 patient, the lesion progressed to squamous cell carcinoma 6 months after release from hospital and 3 years after the first signs of this lesion. The affected limb had to be amputated. Table 1.Characteristics of Patients Presenting a Buruli Ulcer Lesion Undergoing Spontaneous HealingPatientAge, Years/SexClinical FormSitePatient Delay, WeeksHospital Stay, DaysAntibioticsSurgeryPCRCultureDSEPhysical Impairment, ArrivalPhysical Impairment, FinalSquamous Cell Carcinoma17/FULL\>5273C/RNoNANANA11029/MUUL3078S/RYes+−+00037/MUUL\>52105S/RYes+−+110414/MUUL\>52219S/RYes+−−110518/MULL\>5256S/RNo−−−110620/FUUL\>52155S/RYes−−−111710/MUUL\>5299S/RYes+−+110865/FUUL5256C/RNo+−−000925/FUUL1875S/RYes+−+1001055/FUUL\>52122C/RYes+−−000115/MUUL\>52127C/RYes−−−110126/MUUL52152S/RYes+++100MeanAge 20U83% LL\>52110100%75%73%9%36%75%58%8%[^1] Figure 2.Typical case of group 1 spontaneous healing in progress (*Mycobacterium ulcerans* lesions with evidence of healing tissues). Clinical examination showed a large ulcer on the outside of the right knee, measuring approximately 10 × 6.5 cm, with a well demarcated border. The base of the ulcer was clean and there was granulation tissue. Partial healing was observed, and peripheral epithelialization was associated with adhesions restricting the motion of the joint. The black dotted line circumscribes the ulcerative area. Abbreviations: Ad, adhesion; E, peripheral epithelialization; Gt, granuloma tissue.

Group 2: Active Buruli Ulcer Lesion After Initial Spontaneous Healing {#s2d}
---------------------------------------------------------------------

There were 13 patients in this group (n = 13): 8 were male (median age = 10 years) and 5 were female (median age = 40 years) (Table [2](#OFW013TB2){ref-type="table"}). Patients presented 1 (77%) or multiple (23%) active Buruli ulcer lesions, with bone involvement in 40% of the patients, mostly on the lower limbs. All of the active lesions were biologically confirmed, at least by PCR. There was frequently a long interval between the onset of symptoms and consultation, with 77% of patients waiting more than 1 year after the onset of the active lesion before seeking medical attention (Table [2](#OFW013TB2){ref-type="table"}). Table 2.Characteristics of Patients With an Active Buruli Ulcer Lesion Some Distance From a Spontaneously Healed LesionPatientAge, Years/SexClinical FormSiteNumber of Active lesionsDistant ScarPatient Delay, WeeksHospital Stay DaysAntibioticsSurgeryPCRCultureDSEPhysical Impairment, ArrivalPhysical Impairment, FinalTime to Second Lesion, Weeks^a^Squamous Cell Carcinoma110/FEUOsC2 LL2LL\>52240S/RYes+ 2 UL−−11\>520212/MUOsCLL, UL2Back\>52405S/RYes+ UL, LL+ UL+ UL, LL11\>520356/FUC2 UL\>22 UL\>52120S/RYes+ UL−+ UL11\>520470/MEUCUL1UL\>5255S/RYes+−+11NA0545/FQUCUL1UL2455S/RNo+++008068/MQCUL1UL1240S/RYes+−+0040728/MUCUL1UL\>52120S/RYes+−−11\>52187/MOsCUL1Abdomen\>5257S/RYes+−+11\>520916/FUCUL1UL5268S/RYes+−+0040107/MOsC2 LL, 2 UL12 UL, 1LL\>5270S/RYes+ UL−−1180115/MUCButtock1Head3665C/RYes+ Buttock+−003601240/FUCUL1UL\>52125S/RYes+−+11\>5201313/MOsC2 UL, 1 LL\>2UL, LL\>52155S/RYes+ UL, LL−+ LL11\>520MeanAge 2438% Os92% LL30% multi\>52121100%92%100%23%69%69%69%\>528%[^2][^3]

During medical examination, 1 or several stellate scars were observed, some distance away from the active lesion (Figure [3](#OFW013F3){ref-type="fig"}). The scars were located on the same lower limb as the active lesion, on the contralateral lower limb, upper limbs, abdomen, or head (Table [2](#OFW013TB2){ref-type="table"}). The history of the previous lesions and the appearance of the scars were consistent with the spontaneous healing of an old Buruli ulcer lesion. The interval between total healing of the previous lesion and the occurrence of the active lesion was highly variable: from 4 weeks to more than 1 year. Biological confirmation of *M ulcerans* infection was not performed on healed tissues at the consultation. However, in 2 cases, the need for surgery to minimize functional impairment made it possible to confirm the presence of *M ulcerans* DNA in the healed tissues. Figure 3.Typical group 2 clinical form (old spontaneously healed Buruli ulcer and an active lesion \[n = 13\]). The patient presented (A) a stellate scar on the upper part of the right arm, 8 cm in diameter (B) a typical active *Mycobacterium ulcerans* ulcerative lesion on the left foot, measuring approximately 10 × 5 cm). The lesion had undermined edges and was painless. *Mycobacterium ulcerans* infection was confirmed by polymerase chain reaction and acid-fast bacilli on tissue extracted from this lesion. The yellow dotted line circumscribes the scar area with a stellate appearance (edema). The white dotted line circumscribes the active lesion (ulceration).

On arrival, most patients (70%) presented physical impairments due to the spontaneously healed old lesion or the active lesion. After drug treatment (100% of patients) and surgery (92% patients), the patients continued to display functional damage. Limb amputation was required in 1 patient, due to the development of a squamous cell carcinoma at the site of the treated lesion after the completion of drug treatment. Hospital stay exceeded 120 days for 46% of the patients, due to the presence of extensive or multifocal lesions, osteomyelitis, or physical impairment.

Group 3: Complete Spontaneous Healing {#s2e}
-------------------------------------

One patient (n = 1) presented *M ulcerans* infection progressing spontaneously towards complete healing without treatment. The patient, a 27-year-old woman, presented a typical painless nodule (3 cm diameter) on the right arm. Fine-needle aspiration was performed on the nodule to confirm *M ulcerans* infection \[[@OFW013C33], [@OFW013C34]\]. *Mycobacterium ulcerans* was detected by PCR and Ziehl-Neelsen staining. Nodule excision or antibiotic treatment was refused by the patient. Two months after the first consultation, medical staff visited the patient and found that the nodule had disappeared, with a small induration in its place. During interviews, the patient and her family indicated that the patient had received no drug treatment or traditional treatment. Three months later, the patient was seen again. No active lesion was detectable and a small scar was visible (Figure [4](#OFW013F4){ref-type="fig"}). She was seen again 3 years later and had suffered no relapse during this period. This clinical case highlights the ability of some *M ulcerans* lesions to resolve spontaneously. Figure 4.Complete spontaneous healing of a *Mycobacterium ulcerans* lesion. Scar resulting from the spontaneous complete healing of a nodule in a woman who received no treatment.

DISCUSSION {#s3}
==========

Spontaneous healing is known to occur in most infectious diseases \[[@OFW013C35]--[@OFW013C38]\]. However, there have been few descriptions of spontaneous healing in cases of *M ulcerans* infection. There is no medical consensus concerning the relevance of this process in this disease, mostly due to the lack of epidemiological studies. In this context, we conducted the first retrospective study of spontaneous healing, in which we reviewed 545 cases of Buruli ulcer.

We included 26 (4.7%) Buruli ulcer patients described as "presenting a spontaneous healing process", according to our criteria. In most cases, the spontaneous healing was a lengthy process observed in old extensive Buruli ulcer lesions. The delay in seeking medical attention resulted in irreversible physical impairment in most patients. Furthermore, 2 patients subsequently displayed squamous cell carcinoma, which is not surprising because the depigmented scar of a healed lesion on black skin is a risk factor of this cancer.

Spontaneous healing may manifest in different ways, as highlighted by the 3 different clinical groups defined in this study. In group 1, the patients had old ulcerative lesions that were healing. This form is not typical of active Buruli ulcer lesions and its diagnosis is difficult, particularly given the difficulty obtaining samples for biological confirmation (absence of an undermined edge). Moreover, there are several differential diagnoses (varicose ulcers, for example), and the history of the disease recorded during the patient interview is critical to facilitate diagnosis. The patients in group 2 had an active lesion occurring at some distance from a typical Buruli ulcer scar \[[@OFW013C26], [@OFW013C27], [@OFW013C30]\]. Again, the history of this lesion is the key to associating the scar with a typical Buruli ulcer that healed spontaneously.

These observations of a spontaneous healing process demonstrate that patients can develop an immune response able to counteract the effects of *M ulcerans* and mycolactone and to promote tissue remodeling. The occurrence of a second active Buruli ulcer lesion at some distance from a healed lesion suggests that the immune response involved in healing cannot sterilize the tissue, or even confer protection against *M ulcerans*. Therefore, the development of a vaccine against *M ulcerans* may be compromised. It seems unlikely that the occurrence of a second lesion is due to a second contamination event involving the inoculation of the skin with the bacillus. Given the high rate of osteomyelitis observed in second lesions, it seems more likely that *M ulcerans* disseminates systemically, as suggested by other studies \[[@OFW013C14], [@OFW013C16], [@OFW013C19], [@OFW013C24]\].

The single patient in group 3 provides a formal demonstration of the possibility of spontaneous healing of Buruli ulcer without the intervention of Western or traditional medicine. It is reasonable to assume that the number of cases of spontaneous healing is underestimated, because patients do not seek medical assistance for small, painless cutaneous lesions. Even though we cannot exclude that patients used traditional therapies before visiting the doctor, the potential impact of such therapies on the course of the disease remains highly speculative.

Finally, this study raises key questions about the contribution of bacterial and host factors to the documented heterogeneity of the clinical presentation of Buruli ulcer. We cannot rule out the possibility that bacterial strain affects virulence, adaptation, and ability to modulate the immune response. However, this effect is not likely to be the key determinant, because molecular \[[@OFW013C39]\] epidemiological studies have shown that *M ulcerans* diversity is poor (within the same endemic area). In this context, our results suggest that host genetic factors are the key determinants of pathogen control governing the initiation of spontaneous healing.

CONCLUSIONS {#s4}
===========

It is not currently possible to characterize the pathophysiological aspects of spontaneous healing in patients with Buruli ulcer, given the small number of patients identified to date, the difficulty obtaining access to patients in areas where Buruli ulcer is endemic, and for ethical reasons. Furthermore, there is currently no satisfactory experimental model for dissecting the molecular pathway underlying the process of spontaneous healing in Buruli ulcer, and such a model would facilitate the development of treatments to induce healing in patients.
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[^1]: Abbreviations: C/R, clarithromycin and rifampicin; DSE, direct smear examination; LL, lower limb; NA, not available; PCR, polymerase chain reaction; S/R, streptomycin and rifampicin; U, ulcer; UL, upper limb.

[^2]: Abbreviations: C/R, clarithromycin and rifampicin; DSE, direct smear examination; E, edema; LL, lower limb; Os, osteomyelitis; Q, plaque; S/R, streptomycin and rifampicin; U, ulcer; UL, upper limb.

[^3]: ^a^Time to second lesion provided by patient history.
